BACKGROUND AND PURPOSE Vitamin D deficiency is a recognized risk factor for multiple sclerosis (MS) and is associated with increased disease activity. It has also been proposed that the lower the vitamin D levels are, the higher is the handicap. METHODS To refine the links between vitamin D insufficiency and disability in MS patients, a retrospective cohort analysis was performed including 18...

BACKGROUND Patient outcomes in multiple sclerosis (MS) have generally been measured by their neurological impairment using specific scales such as the Kurtzke Expanded Disability Status Scale (EDSS). However, this scale does not measure the multiple dimensions of health-related quality of life (HRQOL) such as functional status and general well-being, which are also important outcomes along with...

Background: Mesenchymal stem cell therapy has been used in multiple sclerosis (MS) in order to modulate the course of the disease in previous studies. One of the major concerns in such cases is long term safety or efficacy of this type of therapy. Objectives: This study was conducted to report the clinical status of five patients with secondary progressive multiple sclerosis and one patient wit...

Probing the cortic ospinal tract integrity by transcranial magnetic stimulation (TMS) could help to understand neurophysiological correlations of multiple sclerosis (MS) symptoms. Therefore, study objective was, first, investigate TMS measures (resting motor threshold-RMT, evoked potential (MEP) latency, and amplitude) corticospinal in people with relapsing-remitting MS (pwMS). Then, examined c...

The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modifying therapy. Two hundred and thirty-two patients received at least one GA dose since study initiation in 1991 (mITT cohort), and 100 (43%, Ongoing c...

BACKGROUND Individual functional system scores (FSS) of the Expanded Disability Status Scale (EDSS) play a central role in determining the overall EDSS score in patients with early-stage multiple sclerosis (MS). Alemtuzumab treatment improves preexisting disability for many patients; however, it is unknown whether improvement is specific to certain functional systems. OBJECTIVE We assessed th...

OBJECTIVE To investigate the value of Expanded Disability Status Scale (EDSS) worsening sustained for at least 6 months and other parameters as predictors for disability status. DESIGN Retrospective analysis of the Multiple Sclerosis Collaborative Research Group study data. SETTING The intramuscular interferon beta-1a pivotal trial was a double-blind, placebo-controlled phase 3 study. PAR...

background: in adults, throughout life, uniqueness maintains the equivalent; but, it might be tailored in the track of neurological disarrays. as in the partition of cognitive function associated with multiple sclerosis (ms), numerous studies have been performed, but there are very few reports in this area of behavior. the aim of this study was to investigate the prevalence of personality types...

OBJECTIVE The aim of this study was to evaluate the association between different disability states in patients with multiple sclerosis (MS) as determined by the expanded disability status scale (EDSS) and dental-periodontal measures. SUBJECTS AND METHODS Eighty patients with MS (64 females and 16 males) were included in this study. Data on MS types, attack frequency, disease duration, EDSS s...

BackgroundAnti-CD20 antibody therapy may be associated with an increased risk of infections. We therefore investigated factors for infection in patients demyelinating diseases treated anti-CD20 therapy.MethodsIn this retrospective uncontrolled study, ever antibodies at academic clinic were identified through the Danish Multiple Sclerosis Registry (DMSR). Data collected from medical charts and D...